In FLT3-mutated AML patients not eligible for intensive chemotherapy, a phase 3 trial evaluated gilteritinib with AZA versus AZA alone; there was a statistically significant difference in composite complete remission rates between gilteritinib/AZA (58.1%) versus AZA alone (26.5%), though it failed to meet the primary objective of a statistically significant median OS difference [31]. This evidence concerns the gene FLT3 and acute myeloid leukemia.